spacer
home > ict > winter 2018 > assessing attitudes
PUBLICATIONS
International Clinical Trials

Assessing Attitudes

Achieving high levels of patient recruitment, adherence, and retention is essential for the successful completion of a clinical trial, yet it remains a significant challenge faced by researchers. Poor patient recruitment, adherence, and retention can adversely affect a trial by lengthening timelines, adding cost and risk to the validity of the data and delaying product approval.

Numerous factors contribute to the process of attracting the patient to consider participating in clinical research studies. These include lacking an awareness of the critical role that clinical trials play; limited access to knowledge about clinical trials; lack of understanding about rights; and safety and benefits. These are among the most common reasons for low participation. In terms of retention in the trial, these can involve patient-centred factors, such as demographic and psychosocial, comprising of their beliefs; attitudes, motivation and severity; therapy-related factors such as treatment complexity adverse reactions and lack of therapeutic impact; and social and economic factors, including the inability to take time off work, lifestyle patterns, etc. Other factors could include clinical trial site location, frequency of clinic visits and clinic staff. In contrast, patients are motivated to participate in clinical trials for reasons including advancing their medical knowledge and gaining access to promising treatment.

The development and integration of patient recruitment and retention strategies that address the issues of a patient’s perceived benefits, barriers, and burden by leveraging both technology and communication is essential to address patient recruitment. However, an additional challenge exists that researchers should consider when developing such strategies. This is the need to take into account the subtle and complex mechanisms that shape people’s behaviour such as whether or not to participate in a clinical trial. This requires an approach, which, to quote Jules Berry, “shines a light on the factors that influence our actions” in an attempt to better understand the subtle and complex mechanisms that impact patient behaviour. It is, to paraphrase Jules Berry, to view the solutions through the prism of Behavioural Economics (BE) (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Keith Meadows has held academic posts at the Universities of London, Newcastle and Hull, UK, undertaking research across much of Europe, including Russia, Spain, Scandinavia and the Low Countries. He has broad experience in health services research, with particular emphasis on the assessment of the psychosocial impact of living with diabetes, health-related quality of life, health survey research and patient-reported outcome measures. Keith founded DHP Research & Consultancy in 2009 to provide research support and training to the healthcare sector, as well as bring innovative approaches to survey and questionnaire design, qualitative data collection and analysis.
spacer
Keith Meadows
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

POP TEST ADDRESSES THE PROBLEM OF UNRELIABLE DATA FROM CONTINUOUS GLUCOSE MONITORS

A major insight relating to the unreliability of data from continuous glucose monitors was published in the Nature journal, “Scientific Reports”, by Neil Theise, MD., the Lead Scientist of Pop Test, LLC and colleagues. The discovery of the “Interstitium”, a newfound human organ, by Dr. Theise and his collaborators, can be viewed by using the link https://www.nature.com/articles/s41598-018-23062-6 Continual glucose monitoring via an indwelling cutaneous needle measuring glucose in interstitial fluid (now identified to be in the “interstitium”) has been a game changer in the treatment of type 1 diabetes mellitus because of its accuracy. However, the needles used to collect this glucose containing fluid often fail in as little as a week. Despite the reliance on fluid from this space, the microanatomy of the interstitium has never been defined. The sensors currently in use were developed with the presumption of interstitial fluid being located somewhere in the sub-epidermal layers of the skin, but the actual anatomy relating to needle placement was always unclear.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

 
Industry Events

Symposium on Digitalization and Big Data in Biotech and Pharma

6 June 2018, ETH Zurich, Institute for Chemical and Bioengineering, Vladimir-Prelog-Weg 1

The Symposium on Digitalization and Big Data in Biotech & Pharma will bring together experts and key stakeholders from industry and academia to discuss and current digital innovations and technological trends in the pharmaceutical sector.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement